The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Endostar plus gemcitabine/cisplatin (GP) with maintenance endostar as first-line therapy for advanced non-small cell lung cancer (NSCLC): Preliminary results of a phase II study.
You Lu
No relevant relationships to disclose
Meijuan Huang
No relevant relationships to disclose
Qingxia Fan
No relevant relationships to disclose
Qi Wu
No relevant relationships to disclose
Jin Wang
No relevant relationships to disclose
Lu Li
No relevant relationships to disclose
Xi Zhang
No relevant relationships to disclose
Chengye Guo
No relevant relationships to disclose
Wenhui Li
No relevant relationships to disclose
Feng Peng
No relevant relationships to disclose
Xuenong Ouyang
No relevant relationships to disclose
Ding Yu
No relevant relationships to disclose
Xiaohong Cai
No relevant relationships to disclose
Yong Xu
No relevant relationships to disclose
Mei Hou
No relevant relationships to disclose
Rongcheng Luo
No relevant relationships to disclose
Tao Zhang
No relevant relationships to disclose